Safety Study of CTS21166 to Treat Alzheimer Disease

Status:
Completed

Trial end date:
2008-02-01

Target enrollment:

Participant gender:

This study is the first human exposure for the drug candidate CTS21166 in healthy male volunteers

Phase 1

CoMentis